🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dramatic progress in myeloma over last 20 years. Small font but download and use. 19 new drug approvals in 20 years.

#Myeloma Paper of the Day: Long-term follow-up of venetoclax monotherapy in previously treated #Waldenström macroglobulinemia shows median PFS 36 mos, median treatment-free survival 43 mos, no BCL2 G101V mutations in 52 CD19-selected samples: pubmed.ncbi.nlm.nih.gov/40674749/. #mmsm

Somewhat expected given STARGLO ODAC vote in May. Hopefully not a sign of things to come for Blenrep. #mmsm #lymsm Lack of US Data Stymie Roche’s Earlier-Stage Lymphoma Push for Columvi biospace.com/fda/lack-of-us…

Out today in ⁦Leukemia Journal⁩ Our study of Erythroid-predominant MDS with distinct genotypes and associated with prognostic and therapeutic implications. #MDSsm #hemepath ⁦Guillermo Montalban-Bravo⁩ Alex Bazinet, ⁦ nature.com/articles/s4137…

Now let’s see what happens here in the US. PDUFA date is today. Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma #mmsm ⁦⁦nizar jacques bahlis⁩ ca.finance.yahoo.com/news/blenrep-b…

FDA extends review period for GSK’s Blenrep in multiple myeloma #mmsm za.investing.com/news/company-n…

Not really a surprise given last week ODAC. New date is October 23, 2025 #mmsm

A big first for SMM! EU clears J&J's Darzalex as first therapy for smoldering multiple myeloma. Congrats to the entire #myeloma community who fought hard for this to happen #mmsm. firstwordpharma.com/story/5983164

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…

Rewriting Risk: A Data-Driven Look at Myeloma Genetics | Journal of Clinical Oncology #mmsm #bmtsm Journal of Clinical Oncology Krina Patel ascopubs.org/doi/10.1200/JC…

Aiming for 7,000 daily steps can reduce risk of chronic diseases, cognitive decline, and death, finds new study. Explore the research in The Lancet Public Health: hubs.li/Q03yJfrw0

Congrats marivi mateos and Elena Zamagni for the much deserved recognition!! #mmsm #IMS25

Nicely written review on leveraging immunologically based therapies to treat diffuse large B-cell lymphoma #lymsm cell.com/trends/cancer/…

1/ Our call to action is out in Blood Advances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.

6/ Link to #MMsm article in Blood Advances : ashpublications.org/bloodadvances/…

FNIH Program Will Advance Alternative Research Models | FNIH fnih.org/news/fnih-prog…

👉Treatment patterns and blood count control in 10,112 patients with polycythemia vera | ⁦Naveen Pemmaraju, MD⁩ et al #MPNSM tandfonline.com/doi/full/10.10…

ICYMI: Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases brnw.ch/21wUqBg #CHIPsm #clonalhematopoiesis

Now in Journal of Clinical Oncology: ASCO & FDA authors discuss strategies to move away from MTD in oncology 👏 Very relevant to myeloma #MMsm! RW data not mentioned at all, likely for scope - IMO, RW data remain key to optimizing dosing for RW patients after approval. ascopubs.org/doi/full/10.12…

Advances and Challenges in Management of Myelodysplastic Syndromes #MDSsm in our Yale Cancer Center open access free review led by our past 2 fellows Dr Jessica Stempel (now at Uni of Oregon) & Dr tariqkewan (now at Mayo Clinic) mdpi.com/3420652 #mdpicancers via Cancers MDPI